Találati lista | Tudóstér

001-es BibID:	BIBFORM103353
035-os BibID:	(Scopus)85015354198 (WOS)000374833800004
Első szerző:	Kissling, Esther
Cím:	I-MOVE multicentre case-control study 2010/11 to 2014/15 : is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? / E. Kissling, B. Nunes, C. Robertson, M. Valenciano, A. Reuss, A. Larrauri, J. M. Cohen, Beatrix Oroszi, C. Rizzo, A. Machado, D. Pitigoi, L. Domegan, I. Paradowska-Stankiewicz, U. Buchholz, A. Gherasim, I. Daviaud, J. K. Horváth, A. Bella, E. Lupulescu, J. O'Donnell, M. Korczyńska, A. Moren, I-MOVE case-control study team
Dátum:	2016
ISSN:	1560-7917
Megjegyzések:	Since the 2008/9 influenza season, the I-MOVE multicentre case?control study measures influenza vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE against influenza A(H3N2) within the season. Using combined I-MOVE data from 2010/11 to 2014/15 we studied the effects of time since vaccination on influenza type/subtype-specific VE. We modelled influenza type/subtype-specific VE by time since vaccination using a restricted cubic spline, controlling for potential confounders (age, sex, time of onset, chronic conditions). Over 10,000 ILI cases were included in each analysis of influenza A(H3N2), A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influenza positive cases respectively. VE against influenza A(H3N2) reached 50.6% (95% CI: 30.0?65.1) 38 days after vaccination, declined to 0% (95% CI: -18.1?15.2) from 111 days onwards. At day 54 VE against influenza A(H1N1)pdm09 reached 55.3% (95% CI: 37.9?67.9) and remained between this value and 50.3% (95% CI: 34.8?62.1) until season end. VE against influenza B declined from 70.7% (95% CI: 51.3?82.4) 44 days after vaccination to 21.4% (95% CI: -57.4?60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Euro surveillance. - 21 : 16 (2016), p. 1-12. -
További szerzők:	Nunes, Baltazar Robertson, Chris Valenciano, Marta Reuss, Annicka Larrauri, Amparo Cohen, Jean Marie Oroszi Beatrix (1970-) (orvos, epidemiológus) Rizzo, Caterina Machado, Ausenda Pitigoi, Daniela Domegan, Lisa Paradowska-Stankiewicz, Iwona Buchholz, Udo Gherasim, Alin Daviaud, Isabelle Horváth Judit Krisztina Bella, Antonino Lupulescu, Emilia O'Donnell, Joan Korczyńska, Monika Moren, Alain I-MOVE case-control study team
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103350
035-os BibID:	(Scopus)76449094520 (WOS)000272247100007 (cikkazonosító)19388
Első szerző:	Kissling, Esther
Cím:	"I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness : lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9 / E. Kissling, M. Valenciano, J. M. Falcão, A. Larrauri, K. Widgren, D. Pitigoi, B. Oroszi, B. Nunes, C. Savulescu, A. Mazick, E. Lupulescu, B. Ciancio, A. Moren
Dátum:	2009
ISSN:	1025-496X 1560-7917
Megjegyzések:	Within I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE)) five countries conducted IVE pilot case-control studies in 2008-9. One hundred and sixty sentinel general practitioners (GP) swabbed all elderly consulting for influenza-like illness (ILI). Influenza confirmed cases were compared to influenza negative controls. We conducted a pooled analysis to obtain a summary IVE in the age group of ?65 years. We measured IVE in each study and assessed heterogeneity between studies qualitatively and using the I2 index. We used a one-stage pooled model with study as a fixed effect. We adjusted estimates for age-group, sex, chronic diseases, smoking, functional status, previous influenza vaccinations and previous hospitalisations. The pooled analysis included 138 cases and 189 test-negative controls. There was no statistical heterogeneity (I2=0) between studies but ILI case definition, previous hospitalisations and functional status were slightly different. The adjusted IVE was 59.1% (95% CI: 15.3-80.3%). IVE was 65.4% (95% CI: 15.6-85.8%) in the 65-74, 59.6% (95% CI: -72.6 -90.6%) in the age group of ?75 and 56.4% (95% CI: -0.2-81.3%) for A(H3). Pooled analysis is feasible among European studies. The variables definitions need further standardisation. Larger sample sizes are needed to achieve greater precision for subgroup analysis. For 2009-10, I-MOVE will extend the study to obtain early IVE estimates in groups targeted for pandemic H1N1 influenza vaccination.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Eurosurveillance. - 14 : 44 (2009), p. 29-36. -
További szerzők:	Valenciano, Marta Falcão, J. M. Larrauri, Amparo Widgren, K. Pitigoi, Daniela Oroszi Beatrix (1970-) (orvos, epidemiológus) Nunes, Baltazar Savulescu, Camelia Mazick, A. Lupulescu, Emilia Ciancio, Bruno Moren, Alain
Internet cím:	Szerző által megadott URL Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103358
035-os BibID:	(cikkazonosító)e1000388 (WOS)000286594200004 (Scopus)79951650357
Első szerző:	Valenciano, Marta
Cím:	Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009-2010 : results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study / Marta Valenciano, Esther Kissling, Jean-Marie Cohen, Beatrix Oroszi, Anne-Sophie Barret, Caterina Rizzo, Baltazar Nunes, Daniela Pitigoi, Amparro Larrauri Cámara, Anne Mosnier, Judith K. Horvath, Joan O'Donnell, Antonino Bella, Raquel Guiomar, Emilia Lupulescu, Camelia Savulescu, Bruno C. Ciancio, Piotr Kramarz, Alain Moren
Dátum:	2011
ISSN:	1549-1676
Megjegyzések:	Background: A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1). Methods and findings: Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6-85.5) overall; 78.4% (95% CI 54.4-89.8) in patients <65 years; and 72.9% (95% CI 39.8-87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9-84.8), 71.3% (95% CI 29.1-88.4), and 70.2% (95% CI 19.4-89.0), respectively. The adjusted PIVE was 66.0% (95% CI -69.9 to 93.2) if vaccinated 8-14 days before ILI onset. The adjusted 2009-2010 seasonal influenza VE was 9.9% (95% CI -65.2 to 50.9). Conclusions: Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009-2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010-2011 season, when vaccination will occur before the influenza season starts.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	PLoS Medicine. - 8 : 1 (2011), p. 1-12. -
További szerzők:	Kissling, Esther Cohen, Jean Marie Oroszi Beatrix (1970-) (orvos, epidemiológus) Barret, Anne-Sophie Rizzo, Caterina Nunes, Baltazar Pitigoi, Daniela Larrauri Cámara, Amparro Mosnier, Anne Horváth Judit Krisztina O'Donnell, Joan Bella, Antonino Guiomar, Raquel Lupulescu, Emilia Savulescu, Camelia Ciancio, Bruno Kramarz, Piotr Moren, Alain
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: